The European Medicines Agency has advised that for pneumonia, acute bacterial sinusitis, and acute exacerbations of COPD, it should only be used when other antibiotics are inappropriate.
November 2005: Complicated intra-abdominal infections. June 2005: Complicated skin and skin structure infections. May 2004: Community acquired pneumonia caused by multidrug resistant Streptococcus pneumoniae. April 2001: Uncomplicated skin and skin structure infections. Acute exacerbations of chronic bronchitisĪdditional indications approved by the FDA are:. The initial approval by the FDA (December 1999) encompassed these indications: In the US, the marketing approval does not contain these restrictions, though the label contains prominent warnings against skin reactions. Based on its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the by mouth (but not the IV) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis. In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. 
Moxifloxacin is used to treat a number of infections, including: respiratory tract infections, cellulitis, anthrax, intra-abdominal infections, endocarditis, meningitis, and tuberculosis.
0 kommentar(er)
